Dennis Podlesak

Mr. Dennis G.
Podlesak is a Chairman at Syndax Pharmaceuticals, Inc., a Venture Partner at Domain Associates LLC, a Chairman at Adynxx, Inc., a Chairman & Chief Executive Officer at Transposon Therapeutics, Inc. and a Partner at Domain LLC.
He is on the Board of Directors at Domain Russia Investments Ltd. Mr. Podlesak was previously employed as a Chairman by Tobira Therapeutics, Inc., a Chairman by Regado Biosciences, Inc., a Chief Executive Officer & Director by Calixa Therapeutics, Inc., a Chief Executive Officer & Director by Cerexa, Inc., an Independent Director by Avanir Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Peninsula Pharmaceuticals, Inc., a Vice President & Head-Eye Care Division by Allergan, Inc., a Chairman by Adynxx, Inc. (Old), an Executive Chairman by Corthera, Inc., a Principal by GlaxoSmithKline LLC, a Senior VP & Head-North American Business Unit by Novartis AG, and a Member-Executive Committee by Novartis Pharmaceuticals Corp.
He also served on the board at DOV Pharmaceutical, Inc., Adastra Pharmaceuticals, Inc., Exalys Therapeutics, Inc., Kalidex Pharmaceuticals, Inc., National Society to Prevent Blindness and RightCare Solutions, Inc. He received his undergraduate degree from Pepperdine University, an undergraduate degree from Western Illinois University, a graduate degree from The Wharton School of the University of Pennsylvania and an MBA from Pepperdine University.